Krystal Biotech (NASDAQ:KRYS) Issues Earnings Results

Krystal Biotech (NASDAQ:KRYS) issued its earnings results on Monday. The company reported $1.83 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $1.45 by $0.38, FiscalAI reports. Krystal Biotech had a net margin of 52.64% and a return on equity of 18.69%. The company had revenue of $116.36 million during the quarter, compared to analyst estimates of $112.11 million.

Krystal Biotech Stock Performance

Krystal Biotech stock opened at $266.04 on Monday. Krystal Biotech has a 1-year low of $122.80 and a 1-year high of $298.30. The firm’s fifty day simple moving average is $261.72 and its 200-day simple moving average is $246.50. The company has a market capitalization of $7.83 billion, a P/E ratio of 38.84 and a beta of 0.50.

Wall Street Analyst Weigh In

A number of equities analysts have recently weighed in on the stock. HC Wainwright reaffirmed a “buy” rating and issued a $310.00 price target (up from $240.00) on shares of Krystal Biotech in a research note on Friday, January 9th. Chardan Capital boosted their target price on Krystal Biotech from $220.00 to $323.00 and gave the company a “buy” rating in a research note on Wednesday, February 18th. TD Cowen reaffirmed a “buy” rating on shares of Krystal Biotech in a research report on Friday, January 9th. The Goldman Sachs Group raised their price target on Krystal Biotech from $206.00 to $327.00 and gave the stock a “buy” rating in a research note on Friday, January 30th. Finally, Guggenheim lifted their price target on Krystal Biotech from $224.00 to $284.00 and gave the company a “buy” rating in a report on Wednesday, February 25th. Nine equities research analysts have rated the stock with a Buy rating and two have issued a Hold rating to the company’s stock. According to MarketBeat.com, Krystal Biotech presently has a consensus rating of “Moderate Buy” and a consensus price target of $326.25.

Insider Buying and Selling at Krystal Biotech

In other Krystal Biotech news, Director Dino A. Rossi sold 18,950 shares of the business’s stock in a transaction dated Thursday, February 19th. The stock was sold at an average price of $261.41, for a total value of $4,953,719.50. Following the completion of the sale, the director owned 78,691 shares of the company’s stock, valued at $20,570,614.31. The trade was a 19.41% decrease in their ownership of the stock. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available at this hyperlink. Also, insider Suma Krishnan sold 25,000 shares of the company’s stock in a transaction dated Wednesday, March 4th. The stock was sold at an average price of $263.21, for a total value of $6,580,250.00. Following the sale, the insider owned 1,403,155 shares of the company’s stock, valued at approximately $369,324,427.55. This trade represents a 1.75% decrease in their position. The SEC filing for this sale provides additional information. Over the last three months, insiders have sold 129,164 shares of company stock valued at $34,538,578. Company insiders own 13.10% of the company’s stock.

Institutional Inflows and Outflows

Institutional investors have recently made changes to their positions in the stock. Royal Bank of Canada boosted its position in Krystal Biotech by 145.2% during the first quarter. Royal Bank of Canada now owns 1,628 shares of the company’s stock worth $294,000 after purchasing an additional 964 shares during the period. AQR Capital Management LLC raised its position in shares of Krystal Biotech by 29.9% in the first quarter. AQR Capital Management LLC now owns 12,131 shares of the company’s stock valued at $2,187,000 after purchasing an additional 2,792 shares during the period. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. raised its position in shares of Krystal Biotech by 4.5% in the first quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. now owns 15,893 shares of the company’s stock valued at $2,870,000 after purchasing an additional 688 shares during the period. Empowered Funds LLC acquired a new stake in shares of Krystal Biotech in the first quarter worth $218,000. Finally, Cetera Investment Advisers lifted its stake in shares of Krystal Biotech by 107.9% in the second quarter. Cetera Investment Advisers now owns 4,344 shares of the company’s stock worth $597,000 after buying an additional 2,255 shares during the last quarter. 86.29% of the stock is owned by institutional investors.

Krystal Biotech Company Profile

Krystal Biotech, Inc is a clinical-stage biotechnology company focused on developing gene therapies for rare dermatological diseases. Headquartered in Pittsburgh, Pennsylvania, the company applies proprietary viral vector delivery technology to enable topical administration of corrective genes directly to the skin. By targeting the underlying genetic causes of inherited skin disorders, Krystal Biotech seeks to address areas of high unmet medical need with potentially transformative treatments.

The company’s lead product candidate, KB103, is designed to deliver a functional COL7A1 gene to patients with dystrophic epidermolysis bullosa (DEB), a severe and often debilitating blistering condition.